Skip to main content

Table 2 Characteristics of study population

From: Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso

Characteristics Women infected at ANC-1 (enrolment) (N = 120) Women infected at Delivery (N = 120) Women infected at ANC-1 and at delivery (N = 42) P
Age at enrolment (years, mean ± SD) 23.9 (±5.7) 26.5 (± 6.1) 21.5 (5.6)  < 0.001
Parasite density by LM (parasites/μl, Median (IQR))
 ANC-1 903 (324.5–2308.5) 1752.5 (558.5–5373.5) 0.01
 Delivery 1955.7 (565.2–9733) 2268 (835–15,485) 0.84
MiP preventive strategy
 IPTp-SP 67 (55.8) 58 (48.3) 20 (47.6) 0.40
 CSST/IPTp-SP 53 (44.2) 62 (51.7) 22 (52.4)  
Gravidity
  ≤ 2 63 (52.5) 35 (29.2) 32 (76.2)  < 0.001
  > 2 57 (47.5) 85 (70.8) 10 (23.8)  
ITN usagea
 Night before ANC-1 103 (92.8) 24 (72.7) 0.004
 Night before delivery 69 (62.2) 24 (72.7) 0.30
IPTp-SP doses during pregnancy
 < 3 82 (68.3) 33 (78.6) 0.21
  ≥ 3 38 (31.7) 9 (21.4)  
AL treatment during pregnancy
 0 67 (55.8) 13 (31.0) 0.02
 1 33 (27.5) 19 (45.2)  
 ≥ 2   20 (16.7) 10 (23.8)  
Timing AL treatment to delivery
 No treatment   67 (55.8) 13 (31.0) 0.05
 4 to 28 days 18 (15.0) 8 (19.0)  
 29 to 42 days 13 (10.8) 10 (23.8)  
 43 to 63 days   13 (10.8) 5 (11.9)  
  ≥ 64 days   9 (7.5) 4 (14.3)  
Haemoglobin level at deliverya
 < 11 g/dl 63 (53.4) 20 (50.0) 0.72
 ≥ 11 g/dl 55 (46.6) 20 (50.0)  
Malaria episode during pregnancy
 ≤ 2 58 (48.3) 0 (0.0)  < 0.001
 > 2 62 (51.7) 42 (100)  
Triple dhfr 51/59/108 mutation at deliverya
 No   19 (28.8) 6 (35.3) 0.60
 Yes   46 (71.2) 11 (64.7)  
  1. a Missing: ITN usage (women infected only at ANC-1 (N = 111), women infected only at delivery (N = 111), Women infected both at ANC-1 and at delivery (N = 33)); Haemoglobin level at delivery (women infected only at delivery (N = 118), Women infected both at ANC-1 and at delivery (N = 40)); Triple dhfr 51/59/108 mutation (Women infected only at delivery (N = 66), Women infected both at ANC-1 and at delivery (N = 17)